December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Annexon Biosciences

< Previous 1 2 3 Next >
News headline image
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Biosciences to Participate in Upcoming September Investor Conferences
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
News headline image
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
From Annexon Biosciences
Via GlobeNewswire
Tickers ANNX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.